Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Woohwangchungsim-won plus donepezil for behavioral and psychological symptoms of dementia (Alzheimer's disease)
KCT0005669Phase 2
Key facts
- Status
- Recruiting
- Start
- Dec 2020
- Countries
- 1
- Sponsor
- Korea Health Industry Development Institute
- Modality
- Small Molecules
- Drugs
- donepezil
- Conditions
- Alzheimer's disease (AD)
01
Overview
Phase 2, randomised trial of donepezil in Alzheimer's disease (AD) (2 arms), sponsored by Korea Health Industry Development Institute. Started Dec 2020; status: recruiting.
02
Design
2 arms- Study design
- Randomized
Donepezil alone
Standard donepezil therapy for Alzheimer's disease dementia; serves as active control for evaluation of added Woohwangchungsim-won.
Woohwangchungsim-won plus donepezil
Combination of Woohwangchungsim-won with standard donepezil therapy to assess added efficacy and safety for behavioral and psychological symptoms of dementia.
03
Who it enrols
Adults with Alzheimer's disease dementia presenting with behavioral and psychological symptoms; detailed inclusion and exclusion criteria are not reported in the available registry entry.
Beyond the preview
Go deeper on KCT0005669.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005669.